Johnson & Johnson Stock Forecast: Trending Bullish Among Analysts

Johnson & Johnson (JNJ) stock has risen 59.4% over the past year, with a modest 0.2% gain in the last month and a 1.1% dip in the past week. Wall Street’s analysts are moderately bullish, with a 12‑month consensus price target of $260.71 versus the last close at $238.67, implying further upside from here.

Analyst Asad Haider of Goldman Sachs reiterated a Buy rating on JNJ on April 15, 2026, setting a price target of $275, above the Street average. This N‑star analyst ranks 1,979 out of 12,147 on TipRanks, with an impressive 75.68% success rate and an 18.10% average return per rating, adding weight to his positive stance.

Haider highlights that JNJ has now delivered five straight quarters of revenue beats, powered mainly by its Innovative Medicines division. Management also raised 2026 guidance modestly, which the analyst believes may still be conservative given favorable profit dynamics and a stronger impact from new product launches expected in the second half of the year.

According to Haider, the stock’s strong run over the past year has closely followed upward sales revisions, as multiple new product cycles drive an ongoing re‑rating and accelerating growth. Management reiterated confidence in reaching double‑digit revenue growth by the end of the decade, stressing that mergers and acquisitions are not required, since existing products and the pipeline should be enough to hit those goals.

The analyst points to three key growth drivers supporting this optimism, starting with Tremfya, which has been beating expectations by increasingly wider margins, with 2026 forecasts above consensus. He also cites Icotyde, framed by management as a potential $10 billion‑plus product versus current consensus of $7–8 billion, and notes continued momentum from Inlexzo, together reinforcing the case for ongoing upside in JNJ shares. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.